Envision Healthcare Holdings, Inc. (NYSE: EVHC) (the “Company”) announced today the pricing of a secondary offering of 27.5 million shares of its common stock by certain stockholders of the Company at a public offering price of $30.50 per share. Investment funds sponsored by, or affiliated with, Clayton, Dubilier & Rice, LLC and certain executive officers and employees of the Company will be the selling stockholders. In connection with the offering, the CD&R investment funds have granted the underwriters an option to purchase up to 4.125 million additional shares of common stock. The Company will not receive any proceeds from the secondary offering. The secondary offering will be made only by means of a prospectus.
Goldman, Sachs & Co., Barclays, BofA Merrill Lynch and Citigroup are serving as lead joint book-running managers and as representatives of the underwriters for the secondary offering. Credit Suisse, Deutsche Bank Securities, Morgan Stanley, RBC Capital Markets and UBS Investment Bank are acting as book-running managers. Jefferies is acting as lead co-manager. Avondale Partners, Cantor Fitzgerald & Co., Oppenheimer & Co., Piper Jaffray and William Blair are acting as co-managers of the offering.
When available, copies of the final prospectus relating to the secondary offering may be obtained from Goldman, Sachs & Co., Attention: Prospectus Department, 200 West Street, New York, New York 10282, or by telephone at 1-866-471-2526, or by facsimile at 1-212-902-9316 or by email at
; Barclays, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: (888) 603-5847, or by e-mail:
; BofA Merrill Lynch, 222 Broadway, New York, NY 10038, Attn: Prospectus Department, email
; or Citigroup, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: (800) 831-9146, or by e-mail:
A registration statement relating to these securities has been filed with, and declared effective by, the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these shares in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any state.